Actively Recruiting
Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy
Led by Tongji Hospital · Updated on 2025-11-21
114
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.
CONDITIONS
Official Title
Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 2-12 years
- ASA physical status I-II
- Body mass index (BMI): 14-28 kg/m8
- Scheduled for elective tonsillectomy with or without adenoidectomy
- Signed informed consent by legal guardian(s) and assent by children (68 years old)
You will not qualify if you...
- History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)
- Previous episodes of significant perioperative respiratory adverse events
- Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)
- Comorbidities including uncorrected congenital heart disease, neuromuscular disorders, developmental delay, abnormal hepatic or renal function
- Preoperative moderate-to-severe respiratory infections requiring surgery postponement
- Recent participation in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
P
Pu Zhou
CONTACT
A
Aihua Du
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here